Briefing Summary: US FDA Posts Advisory Committee Materials for Ardea’s Lesinurad for Gout – OCT 23, 2015 (AAC)

The US FDA has posted details, including Company and FDA Briefing Materials, for the Friday, October 23, 2015 Arthritis Advisory Committee (AAC) meeting. The Committee will discuss lesinurad oral tablets, submitted by Ardea Biosciences, Inc. (Ardea), for the treatment of hyperuricemia associated with gout, in combination with a xanthine oxidase inhibitor. As of June 2012, Ardea has been a wholly-owned subsidiary of AstraZeneca, Inc.

See the SAC Tracker report